These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31943236)

  • 1. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.
    Singh AD; Maitra S; Singh N; Tyagi P; Ashraf A; Kumar R; Shalimar
    Aliment Pharmacol Ther; 2020 Mar; 51(5):490-504. PubMed ID: 31943236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
    Krishnan P; Pilot-Matias T; Schnell G; Tripathi R; Ng TI; Reisch T; Beyer J; Dekhtyar T; Irvin M; Xie W; Larsen L; Mensa FJ; Collins C
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
    Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
    J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
    Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
    Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis.
    Zhang Y; Jiang X; Zhao Y; Xu Y
    J Viral Hepat; 2021 Jan; 28(1):177-185. PubMed ID: 32961624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    Wang GP; Schnell GL; Kort JJ; Sidhu GS; Schuster L; Tripathi RL; Larsen L; Michael LC; Bergquist K; Magee A; Patel CB; Whitlock JA; Tamashiro R; Peter JA; Fried MW; Nelson DR
    J Hepatol; 2021 Oct; 75(4):820-828. PubMed ID: 34023351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
    PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
    Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
    Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
    Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
    Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
    Wyles D; Poordad F; Wang S; Alric L; Felizarta F; Kwo PY; Maliakkal B; Agarwal K; Hassanein T; Weilert F; Lee SS; Kort J; Lovell SS; Liu R; Lin CW; Pilot-Matias T; Krishnan P; Mensa FJ
    Hepatology; 2018 Feb; 67(2):514-523. PubMed ID: 28926120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    Garcia-Cehic D; Rando A; Rodriguez-Frias F; Gregori J; Costa JG; Carrión JA; Macenlle R; Pamplona J; Castro-Iglesias A; Cañizares A; Tabernero D; Campos C; Buti M; Esteban JI; Quer J
    J Viral Hepat; 2021 Sep; 28(9):1319-1324. PubMed ID: 33720484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
    J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
    Nozaki A; Atsukawa M; Kondo C; Toyoda H; Chuma M; Nakamuta M; Uojima H; Takaguchi K; Ikeda H; Watanabe T; Ogawa S; Itokawa N; Arai T; Hiraoka A; Asano T; Fujioka S; Ikegami T; Shima T; Ogawa C; Akahane T; Shimada N; Fukunishi S; Abe H; Tsubota A; Genda T; Okubo H; Mikami S; Morishita A; Moriya A; Tani J; Tachi Y; Hotta N; Ishikawa T; Okanoue T; Tanaka Y; Kumada T; Iwakiri K; Maeda S;
    Hepatol Int; 2020 Mar; 14(2):225-238. PubMed ID: 32128704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.